Hansoh Pharma completed a highly successful Hong Kong IPO, pricing last week at the top end of its range, and then following up with a 37% rise in its first trading session today. The IPO raised $1 billion for the company at a valuation of $10.7 billion. The company is now valued at $14.7 billion. Founded in 1995, Hansoh offers more than 40 products in six therapeutic areas. It also boasts of having a large development pipeline. The enthusiastic reception for Hansoh bodes well for other China IPOs.
Source: China Biotoday
